Centessa Pharmaceuticals Announces Poster Presentation of New Preclinical Data Supporting Expansion of Orexin Receptor 2 (OX2R) Agonist Pipeline into Neuropsychiatric Indications at the 64...
Centessa Pharmaceuticals plc - American Depositary Shares (CNTA)
Company Research
Source: Yahoo! Finance
BOSTON and LONDON, Jan. 14, 2026 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical-stage pharmaceutical company focused on developing transformational medicines, today announced the presentation of new preclinical data showing that OX2R activation with a highly potent and selective OX2R agonist reduced behavioral despair and enhanced wakefulness in an established animal model of major depressive disorder at the 64th Annual Meeting of the American College of Neuropsychopharmacology (ACNP). These results support OX2R activation as a potential mechanism of action for rapid-onset treatment to improve mood symptoms and alleviate hypersomnolence in neuropsychiatric indications. “As a leader in orexin science, we continue to explore orexin pharmacology within a suite of well validated translational non-clinical studies with the goal of unlocking the full potential of our multi-asset OX2R agonist pipeline for patients,” said Mario Alberto Accardi PhD, Chief Execut
Show less
Read more
Impact Snapshot
Event Time:
CNTA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CNTA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CNTA alerts
High impacting Centessa Pharmaceuticals plc - American Depositary Shares news events
Weekly update
A roundup of the hottest topics
CNTA
News
- Centessa Pharmaceuticals (NASDAQ:CNTA) had its "overweight" rating reaffirmed by analysts at Piper Sandler.MarketBeat
- Centessa Pharmaceuticals Announces Poster Presentation of New Preclinical Data Supporting Expansion of Orexin Receptor 2 (OX2R) Agonist Pipeline into Neuropsychiatric Indications at the 64th ACNP Annual MeetingGlobeNewswire
- Centessa Pharmaceuticals (NASDAQ:CNTA) had its "buy" rating reaffirmed by analysts at Cowen Inc.MarketBeat
- Truist Hikes Centessa (CNTA) PT to $33 While Maintaining Consistent 2026 Thesis [Yahoo! Finance]Yahoo! Finance
- Centessa Pharmaceuticals (NASDAQ:CNTA) had its price target raised by analysts at Truist Financial Corporation from $30.00 to $33.00. They now have a "buy" rating on the stock.MarketBeat
CNTA
Earnings
- 8/12/25 - Miss
CNTA
Sec Filings
- 1/7/26 - Form 8-K/A
- 1/2/26 - Form 144
- 12/11/25 - Form 8-K
- CNTA's page on the SEC website